Journal of Antimicrobial Chemotherapy (1999) 43, 309-311
© 1999 The British Society for Antimicrobial Chemotherapy
Brief reports |
Continuous infusion ceftazidime in intensive care: a randomized controlled trial
a Royal Brisbane Hospital, Division of Anaesthesiology and Intensive Care, University of Queensland, Brisbane, Australia b Prince of Wales Hospital, Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong, Hong Kong c Department of Anaesthesia, Christchurch Hospital, Christchurch, New Zealand
We randomized 18 critically ill patients to receive ceftazidime 6 g/day by continuous infusion or bolus dosing (2 g 8 hourly), each with a loading dose of 12 mg/kg ceftazidime. During the first 8 h, plasma ceftazidime concentration fell below 40 mg/L in only one patient (trough 38 mg/L) from the infusion group, compared with eight from the bolus group (2-33 mg/L) for periods ranging from 73 to 369 min. Thereafter all infusion patients remained above 40 mg/L for 40 h of study versus 20-30% of bolus patients. The pharmacokinetic and pharmacodynamic characteristics of ceftazidime suggest that continuous infusions should be clinically investigated in outcome studies.
* Correspondence address: Intensive Care Facility, Royal Brisbane Hospital and University of Queensland, Herston Road, Herston, Brisbane, 4029 Queensland, Australia. Tel:+61-7-3253-8897; Fax:+61-7-3253-3542; E-mail:jlipman{at}gasbone.herston.uq.edu.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Hubert, E. Le Roux, T. Lavrut, B. Wallaert, P. Scheid, D. Manach, D. Grenet, I. Sermet-Gaudelus, S. Ramel, C. Cracowski, et al. Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3650 - 3656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jaruratanasirikul and T. Sudsai Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion J. Antimicrob. Chemother., March 1, 2009; 63(3): 560 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Sakka, A. K. Glauner, J. B. Bulitta, M. Kinzig-Schippers, W. Pfister, G. L. Drusano, and F. Sorgel Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3304 - 3310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Roberts, R. Boots, C. M. Rickard, P. Thomas, J. Quinn, D. M. Roberts, B. Richards, and J. Lipman Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study J. Antimicrob. Chemother., February 1, 2007; 59(2): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DeRyke, J. L. Kuti, D. Mansfield, A. Dana, and D. P. Nicolau Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection Am. J. Health Syst. Pharm., April 15, 2006; 63(8): 750 - 755. [Full Text] [PDF]
|
|
|
|
|
|
S. Jaruratanasirikul, S. Sriwiriyajan, and J. Punyo Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1337 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Alou, L. Aguilar, D. Sevillano, M.-J. Gimenez, O. Echeverria, M.-L. Gomez-Lus, and J. Prieto Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model J. Antimicrob. Chemother., February 1, 2005; 55(2): 209 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Piccoli, M. Larosa, and F. Marchetti Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion J. Antimicrob. Chemother., December 1, 2003; 52(6): 1047 - 1048. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lipman, S. C. Wallis, and R. J. Boots Cefepime Versus Cefpirome: The Importance of Creatinine Clearance Anesth. Analg., October 1, 2003; 97(4): 1149 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jaruratanasirikul and S. Sriwiriyajan Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection J. Antimicrob. Chemother., September 1, 2003; 52(3): 518 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Baririan, H. Chanteux, E. Viaene, H. Servais, and P. M. Tulkens Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units J. Antimicrob. Chemother., March 1, 2003; 51(3): 651 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Viaene, H. Chanteux, H. Servais, M.-P. Mingeot-Leclercq, and P. M. Tulkens Comparative Stability Studies of Antipseudomonal {beta}-Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units) Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2327 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. C. E. Buijk, I. C. Gyssens, J. W. Mouton, A. Van Vliet, H. A. Verbrugh, and H. A. Bruining Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections J. Antimicrob. Chemother., January 1, 2002; 49(1): 121 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Joynt, J. Lipman, C. D. Gomersall, R. J. Young, E. L. Y. Wong, and T. Gin The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients J. Antimicrob. Chemother., April 1, 2001; 47(4): 421 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lipman, S. C. Wallis, and C. Rickard Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2559 - 2561. [Abstract] [Full Text]
|
|